Actelion's Tracleer approved for early-stage PAH in US
This article was originally published in Scrip
Executive Summary
Actelion has received authorisation from the US FDA to extend the label of its oral pulmonary arterial hypertension (PAH) drug, Tracleer (bosentan), to include patients with mild forms of the disease, classified as WHO functional class II.